Literature DB >> 1386563

On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production.

R E Spitzer1, A E Stitzel, G Tsokos.   

Abstract

The antibody to the alternative pathway C3 convertase, designated C3 nephritic factor or C3NeF, is an autoantibody that is produced in everyone from the time of birth. The elaboration of C3NeF utilizes germline V-region genes which undergo antigen-driven affinity maturation, resulting in an autoantibody that is produced in large amounts with high affinity and narrow specificity. Our data also suggest that under normal conditions, the idiotypic network may play an important part in the control of this autoantibody. Further, a defect in the network with loss of control or inappropriate stimulation may be an underlying mechanism in the unrestricted production of C3NeF in patients with membranoproliferative glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386563     DOI: 10.1016/0090-1229(92)90197-v

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  3 in total

Review 1.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

2.  Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.

Authors:  Edwin K S Wong; Holly E Anderson; Andrew P Herbert; Rachel C Challis; Paul Brown; Geisilaine S Reis; James O Tellez; Lisa Strain; Nicholas Fluck; Ann Humphrey; Alison Macleod; Anna Richards; Daniel Ahlert; Mauro Santibanez-Koref; Paul N Barlow; Kevin J Marchbank; Claire L Harris; Timothy H J Goodship; David Kavanagh
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

3.  Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.

Authors:  Danielle Paixão-Cavalcante; Margarita López-Trascasa; Lillemor Skattum; Patricia C Giclas; Timothy H Goodship; Santiago Rodríguez de Córdoba; Lennart Truedsson; B Paul Morgan; Claire L Harris
Journal:  Kidney Int       Date:  2012-08-01       Impact factor: 10.612

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.